Drug intelligence / Profile preview

ribonucleic acid III

Development stage: Unknown
Lead developer: Hangzhou Ausia Biological Technology
Modality: RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intramuscular, Intravenous

Overview

Ribonucleic acid III is an immunomodulatory biological drug extracted from healthy porcine spleen. Approved in China, it is primarily indicated for the treatment of diseases associated with low immune function, such as chronic bronchitis, and serves as an adjuvant therapy for malignant tumors. Ribonucleic acid III acts by enhancing cellular immune function and providing anti-radiation effects, which has been shown in animal models to increase thymus and spleen indices, elevate white blood cell counts, and promote T-lymphocyte activity. It is manufactured and supplied by Hangzhou Ausia Biological Technology under the brand name Aoshun.

Brand names: Aoshun澳顺
Other names: Ribonucleic Acid III for Injection核糖核酸Ⅲ注射用核糖核酸Ⅲ

Beyond the preview

Go deeper on ribonucleic acid III.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ribonucleic acid III.

Explore the full profile